Eric Gutierrez
Cancer Care Ontario
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eric Gutierrez.
BMJ Open | 2013
Michael Brundage; Sophie Foxcroft; Tom McGowan; Eric Gutierrez; Michael B. Sharpe; Padraig Warde
Objectives To describe current patterns of practice of radiation oncology peer review within a provincial cancer system, identifying barriers and facilitators to its use with the ultimate aim of process improvement. Design A survey of radiation oncology programmes at provincial cancer centres. Setting All cancer centres within the province of Ontario, Canada (n=14). These are community-based outpatient facilities overseen by Cancer Care Ontario, the provincial cancer agency. Participants A delegate from each radiation oncology programme filled out a single survey based on input from their multidisciplinary team. Outcome measures Rated importance of peer review; current utilisation; format of the peer-review process; organisation and timing; case attributes; outcomes of the peer-review process and perceived barriers and facilitators to expanding peer-review processes. Results 14 (100%) centres responded. All rated the importance of peer review as at least 8/10 (10=extremely important). Detection of medical error and improvement of planning processes were the highest rated perceived benefits of peer review (each median 9/10). Six centres (43%) reviewed at least 50% of curative cases; four of these centres (29%) conducted peer review in more than 80% of cases treated with curative intent. Fewer than 20% of cases treated with palliative intent were reviewed in most centres. Five centres (36%) reported usually conducting peer review prior to the initiation of treatment. Five centres (36%) recorded the outcomes of peer review on the medical record. Thirteen centres (93%) planned to expand peer-review activities; a critical mass of radiation oncologists was the most important limiting factor (median 6/10). Conclusions Radiation oncology peer-review practices can vary even within a cancer system with provincial oversight. The application of guidelines and standards for peer-review processes, and monitoring of implementation and outcomes, will require effective knowledge translation activities.
Clinical Oncology | 2009
A.C. Whitton; Padraig Warde; M. Sharpe; T.K. Oliver; Kate Bak; Konrad W. Leszczynski; S. Etheridge; K. Fleming; Eric Gutierrez; L. Favell; Esther Green
By minimising the effect of irradiation on surrounding tissue, intensity-modulated radiation therapy (IMRT) can deliver higher, more effective doses to the targeted tumour site, minimising treatment-related morbidity and possibly improving cancer control and cure. A multidisciplinary IMRT Expert Panel was convened to develop the organisational standards for the delivery of IMRT. The systematic literature search used MEDLINE, EMBASE, the Cochrane Database, the National Guidelines Clearing House and the Health Technology Assessment Database. An environmental scan of unpublished literature used the Google search engine to review the websites of key organisations, cancer agencies/centres and vendor sites in Canada, the USA, Australia and Europe. In total, 22 relevant guidance documents were identified; 12 from the published literature and 10 from the environmental scan. Professional and organisational standards for the provision of IMRT were developed through the analysis of this evidence and the consensus opinion of the IMRT Expert Panel. The resulting standards address the following domains: planning of new IMRT programmes, practice setting requirements, tools, devices and equipment requirements; professional training requirements; role of personnel; and requirements for quality assurance and safety. Here the IMRT Expert Panel offers organisational and professional standards for the delivery of IMRT, with the intent of promoting innovation, improving access and enhancing patient care.
Journal of Oncology Practice | 2014
Gunita Mitera; Anand Swaminath; David Rudoler; Colleen Seereeram; Meredith Giuliani; Natasha B. Leighl; Eric Gutierrez; Mark J. Dobrow; Peter C. Coyte; Terence Yung; Andrea Bezjak; Andrew Hope
INTRODUCTION In 25% to 35% of patients with early stage I non-small-cell lung cancer (NSCLC), surgery is not feasible, and external-beam radiation becomes their standard treatment. Conventionally fractionated radiotherapy (CFRT) is the traditional radiation treatment standard; however, stereotactic body radiotherapy (SBRT) is increasingly being adopted as an alternate radiation treatment. Our objective was to conduct a cost-effectiveness analysis, comparing SBRT with CFRT for stage I NSCLC in a public payer system. METHODS Consecutive patients were reviewed using 2010 Canadian dollars for direct medical costs from a public payer perspective. A subset of direct radiation treatment delivery costs, excluding physician billings and hospitalization, was also included. Health outcomes as life-years gained (LYGs) were computed using time-to-event methods. Sensitivity analyses identified critical factors influencing costs and benefits. RESULTS From January 2002 to June 2010, 168 patients (CFRT, n = 50; SBRT, n = 118) were included; median follow-up was 24 months. Mean overall survival was 2.83 years (95% CI, 1.8 to 4.1) for CFRT and 3.86 years (95% CI, 3.2 to not reached) for SBRT (P = .06). Mean costs for CFRT were
Journal of Oncology Practice | 2016
Lindsay Elizabeth Reddeman; Sophie Foxcroft; Eric Gutierrez; Margaret Hart; Elizabeth Lockhart; Marissa Mendelsohn; Michelle Ang; Michael Sharpe; Padraig Warde; Michael Brundage
6,886 overall and
Clinical Oncology | 2010
G. Morton; Cindy Walker-Dilks; Fulvia Baldassarre; D. D’Souza; Conrad Falkson; Deidre L. Batchelar; Eric Gutierrez; Kate Bak
5,989 for radiation treatment delivery only versus
Current Oncology | 2016
Jean Hai Ein Yong; Tom McGowan; Ruby Redmond-Misner; J. Beca; Padraig Warde; Eric Gutierrez; Jeffrey S. Hoch
8,042 and
Journal of Oncology Practice | 2013
Kate Bak; Eric Gutierrez; Elizabeth Lockhart; Michael Sharpe; Esther Green; Sarah Costa; Sherrie Hertz; Leonard Kaizer; Anthtony Whitton; Padraig Warde
6,962, respectively, for SBRT. Incremental costs (incremental cost-effectiveness ratio [ICER]) per LYG for SBRT versus CFRT were
Radiotherapy and Oncology | 2011
Gunita Mitera; Anthony Whitton; Eric Gutierrez; S. Robson
1,120 for the public payer and
International Journal of Radiation Oncology Biology Physics | 2017
Julie Rouette; Eric Gutierrez; Jennifer O'Donnell; Lindsay Elizabeth Reddeman; Margaret Hart; Sophie Foxcroft; Gunita Mitera; Padraig Warde; Michael D. Brundage; Gregory J. Czarnota; Medhat El-Mallah; Conrad Falkson; Fei-Fei Liu; Sunil P.P. Gulavita; William McMillan; Jason R. Pantarotto; Ramana Rachakonda; Nancy Read; Ken Schneider; Sarwat Shehata; Christiaan Stevens; Jonathan Tsao; John Waldron; Woodrow Wells; J. Wright; Michael B. Sharpe; Elizabeth Lockhart; Michael Brundage; Amanda Caissie; Helmut Hollenhorst
942 for radiation treatment alone. Varying survival and labor costs individually (± 20%) created the largest changes in the ICER, and simultaneous adjustment (± 5% to ± 30%) confirmed cost effectiveness of SBRT. CONCLUSION Using a threshold of
Journal of Clinical Oncology | 2014
Michelle Ang; Eric Gutierrez; Nicoda Foster; Lisa Favell; Padraig Warde
50,000 per LYG, SBRT seems cost effective. Results require confirmation with randomized data.